Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,374 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy and safety of selective orexin 2 receptor agonists in narcolepsy type 1: a systematic review and meta-analysis of randomized controlled trials.
Yuan L, Huang YB, Chen YX, Kulachai P, Jin SG, Zheng H. · J Neurol · 2026 · cited 0 timesmeta-analysis, systematic review
- Sodium oxybate for excessive daytime sleepiness in narcolepsy: a systematic review and meta-analysis of randomized placebo-controlled trials.
Kanawjia P, Kanaujia SK, Kumari R. · Daru · 2026 · cited 0 timesmeta-analysis, systematic review
- Prevalence of Sleep Disorders in Patients With Knee, Hip, and Hand Osteoarthritis: A Systematic Review With Meta-Analysis.
Krag-Andersen KK, van Zaane JH, Gaban GLNA, Bricca A, Ferreira P, Hall M, Vaegter HB, Thorlund JB. · J Orthop Sports Phys Ther · 2026 · cited 0 timesmeta-analysis, systematic review
- Short-Term Efficacy and Safety of Oral Selective Orexin-2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta-Analysis of Randomized Trials.
Ali A, Sajjad A, Talha M, Waqar K, Tanveer A, Mehmood A, Wahab A, Shahid MA, Rana OUR, Abdullah A, Sharma MK. · Neuropsychopharmacol Rep · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Plazzi G, Grunstein RR, Mignot E, Lammers GJ, Plante DT, Buntinx E, Del Río Villegas R, Chen H, Lovett A, Doane MJ, Hopkinson C, Rege B, Himes J, Dauvilliers Y. · Lancet Neurol · 2026 · cited 1 timesclinical trial, phase ii, multicenter study
- Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.
Dauvilliers Y, Mignot E, Antczak J, Arnulf I, Barateau L, Buntinx E, Corser B, Iranzo A, Khatami R, Lammers GJ, Lederer K, Nilsen KB, Pizza F, Schmidt MH, Sivam S, Sum-Ping O, Taniguchi M, Zhan S, Abraham A, Cai A, Du Y, Etherton MR, Faessel H, Hsiao S, Kadali H, Koundourakis E, Naylor M, Neuwirth R, Olsson T, Rogers R, Sheikh S, Tanaka S, von Rosenstiel P, von Hehn C, Hang Y, Yao B, Del Rio Villegas R, Plazzi G, The First Light and The Radiant Light. · N Engl J Med · 2026 · cited 3 timesclinical trial, phase iii, multicenter study
- Comparative efficacy, safety, and dosing convenience of wake-promoting agents and sodium oxybate formulations for narcolepsy: a systematic review and network meta-analysis.
Jiang Q, Gu Z. · BMC Neurol · 2026 · cited 0 timesOpen accesscomparative study, systematic review
- Defining a Clinically Meaningful Within-Person Change Threshold for the Psychomotor Vigilance Test in Narcolepsy Type 1.
Harel BT, Pietrzak RH, Dave S, Maruff P, Romero H, Brimmer M, Doll H. · Ther Innov Regul Sci · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Narcolepsy and metabolic disease: A meta-analytic synthesis.
Zhang X, Yin W, Ren J, Zhou X, Zha M, Zong Q, Shen Y, Spruyt K, Zhou J. · Sleep Med Rev · 2026 · cited 1 timesmeta-analysis, systematic review
- Psychometric properties of the novel patient-reported Functional Impacts of Narcolepsy Instrument (FINI) using data from phase 3 clinical trials in narcolepsy type 1.
Romero H, Savva Y, Crawford S, Howerter A, Dave S, Doll H. · Front Neurol · 2026 · cited 0 timesOpen accessclinical trial, phase iii
- Symptom improvement with dosing above 9 g of low-sodium oxybate: effectiveness and safety in participants with narcolepsy in the DUET study.
Simmons JH, Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Whalen M, Kirby MT, Dai J, Cairns A, Bogan RK. · J Clin Sleep Med · 2026 · cited 1 timesOpen accessmulticenter study, clinical trial, phase iv
- Efficacy and Safety of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy and Obstructive Sleep Apnea: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jalal AA, Hussain SI, Khan MS, Khan MS, Siddiqui E, Chandani HK, Karim AJ, Shakir S. · Ann Pharmacother · 2026 · cited 0 timesmeta-analysis, systematic review
- Sleep disturbances in craniopharyngioma: a systematic review and meta-analysis.
Liang Q, Yang T, Hu T, Spruyt K, Zhang X, Li Q. · Pituitary · 2025 · cited 1 timesOpen accessmeta-analysis, systematic review
- Sleep Disorder Phenotypes and the Risk of Incident Heart Failure: <i>A meta-analysis with Mendelian randomization validation</i>.
Yan F, Fan L, Chen Y. · Saudi Med J · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Sleep Disorders and Nonalcoholic Fatty Liver Disease: Evidence From Meta-Analysis and Mendelian Randomization.
Wang H, Huang L, Yu M, Qu S, Wang Y, Cao X, Meng Y, Gao Y, Ding B, Bai W, Yao Y. · J Prev (2022) · 2026 · cited 0 timesmeta-analysis
- Assessing Condition-Specific Adverse Event Profiles of Modafinil for Labelled and Off-Label Uses: A Systematic Review and Meta-Analysis.
Jung J, Youm J, Kang J, Kim AY, Suh JK, Kang HY. · Basic Clin Pharmacol Toxicol · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.
Lammers GJ, Plazzi G, Mignot E, Pizza F, Dauvilliers Y, Barateau L, Maruff P, Scammell TE, Latzman RD, Naylor M, Olsson T, Stukalin E, Tanaka S, Volfson D, Khachadourian V, Harel BT. · JAMA Neurol · 2026 · cited 7 timesOpen accessclinical trial, phase ii, multicenter study
- Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis.
Yan Z, Li J, Yu Y, Qiu S, Wang B, Tang J. · BMC Neurol · 2025 · cited 0 timesOpen accesscomparative study, systematic review
- Glymphatic dysfunction across sleep disorders: a meta-analysis of DTI-ALPS studies.
Zhang X, He D. · Front Neurol · 2026 · cited 2 timesOpen accesssystematic review, systematic-review
- Epidemiology and Economic Burden of Sleep Disorders in Europe.
Bassetti CLA, Welter LS, Montes-Martinez M, Mühlberger N, Boon P, Berger T, Deuschl G, Arvandi M, Konti M, Lolich M, Pajediene E, Fronczek R, Moro E, Siebert U, Dodel R. · Eur J Neurol · 2026 · cited 11 timesOpen accessmeta-analysis
- The Role of Actigraphy in the Assessment of Central Disorders of Hypersomnolence: A Systematic Review and Meta-Analysis.
Maia S, Soares JI, Borges DF, Casalta-Lopes J, Gonçalves M. · Can J Neurol Sci · 2026 · cited 0 timesmeta-analysis, systematic review
- Safety and efficacy of transcutaneous auricular vagus nerve stimulation in patients with narcolepsy type 1 (TARGET-2): study protocol for a randomised, double-blind, sham-controlled trial.
Pan Y, Zhang Y, Hu G, Wang X, Yang L, Yuan N, Jia Y, Hao F, Kang J, Ye H, Wen X, Li C, Zhu Z, Wu D, Wu K, Liu Y, TARGET-2 Trial investigator. · BMJ Open · 2026 · cited 0 timesOpen accessclinical trial protocol
- Insomnia as risk factor for brain, mental and general health consequences: an umbrella systematic review.
Vignatelli L, Leone MA, Pupillo E, Seidel S, Kallweit U, Colorado Prieto N, Lolich M, Tüzün M, Bassetti CLA. · Sleep Med Rev · 2026 · cited 0 timessystematic review, review
- Machine Learning for Diagnosis and Differentiation of Central Disorders of Hypersomnolence: A Systematic Review.
Helmy A, Fregolente LG, von Gernler M, Morand R, van der Meer J, Schmidt M, Mougiakakou S, Tzovara A, Bassetti CLA. · Eur J Neurol · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.
Dauvilliers Y, Plazzi G, Mignot E, Lammers GJ, Del Río Villegas R, Khatami R, Taniguchi M, Abraham A, Hang Y, Kadali H, Lamberton M, Sheikh S, Stukalin E, Neuwirth R, Swick TJ, Tanaka S, von Hehn C, von Rosenstiel P, Wang H, Cai A, Naylor M, Olsson T. · N Engl J Med · 2025 · cited 30 timesclinical trial, phase ii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.